These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 35587713)

  • 41. Combining Donor-derived Cell-free DNA Fraction and Quantity to Detect Kidney Transplant Rejection Using Molecular Diagnoses and Histology as Confirmation.
    Halloran PF; Reeve J; Madill-Thomsen KS; Kaur N; Ahmed E; Cantos C; Al Haj Baddar N; Demko Z; Liang N; Swenerton RK; Zimmermann BG; Van Hummelen P; Prewett A; Rabinowitz M; Tabriziani H; Gauthier P; Billings P;
    Transplantation; 2022 Dec; 106(12):2435-2442. PubMed ID: 35765145
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinical Validation of a Plasma Donor-derived Cell-free DNA Assay to Detect Allograft Rejection and Injury in Lung Transplant.
    Rosenheck JP; Ross DJ; Botros M; Wong A; Sternberg J; Chen YA; Liang N; Baer A; Ahmed E; Swenerton R; Zimmermann BG; Fehringer G; Demko ZP; Olymbios M; Billings PR; Keller BC
    Transplant Direct; 2022 Apr; 8(4):e1317. PubMed ID: 35372675
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Optimizing Detection of Kidney Transplant Injury by Assessment of Donor-Derived Cell-Free DNA via Massively Multiplex PCR.
    Sigdel TK; Archila FA; Constantin T; Prins SA; Liberto J; Damm I; Towfighi P; Navarro S; Kirkizlar E; Demko ZP; Ryan A; Sigurjonsson S; Sarwal RD; Hseish SC; Chan-On C; Zimmermann B; Billings PR; Moshkevich S; Sarwal MM
    J Clin Med; 2018 Dec; 8(1):. PubMed ID: 30583588
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Combining Blood Gene Expression and Cellfree DNA to Diagnose Subclinical Rejection in Kidney Transplant Recipients.
    Park S; Guo K; Heilman RL; Poggio ED; Taber DJ; Marsh CL; Kurian SM; Kleiboeker S; Weems J; Holman J; Zhao L; Sinha R; Brietigam S; Rebello C; Abecassis MM; Friedewald JJ
    Clin J Am Soc Nephrol; 2021 Oct; 16(10):1539-1551. PubMed ID: 34620649
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Multi-centre analytical performance verification of an IVD assay to quantify donor-derived cell-free DNA in solid organ transplant recipients.
    Casas S; Tangprasertchai NS; Oikonomaki K; Mathers S; Sollet ZC; Samara S; Liu J; Burlinson ND; Constantoulakis P; Villard J; Viard T
    HLA; 2024 May; 103(5):e15518. PubMed ID: 38733247
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Biological Variation of Donor-Derived Cell-Free DNA in Stable Lung Transplant Recipients.
    Keller M; Mutebi C; Shah P; Levine D; Aryal S; Iacono A; Timofte I; Mathew J; Varghese A; Giner C; Agbor-Enoh S
    J Appl Lab Med; 2022 Jun; 7(4):901-909. PubMed ID: 35024828
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prognostic value of the donor-derived cell-free DNA assay in acute renal rejection therapy: A prospective cohort study.
    Shen J; Guo L; Yan P; Zhou J; Zhou Q; Lei W; Liu H; Liu G; Lv J; Liu F; Huang H; Dong W; Shu L; Wang H; Wu J; Chen J; Wang R
    Clin Transplant; 2020 Oct; 34(10):e14053. PubMed ID: 32735352
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Donor-derived cell-free DNA as a biomarker for rejection after kidney transplantation: a systematic review and meta-analysis.
    Wijtvliet VPWM; Plaeke P; Abrams S; Hens N; Gielis EM; Hellemans R; Massart A; Hesselink DA; De Winter BY; Abramowicz D; Ledeganck KJ
    Transpl Int; 2020 Dec; 33(12):1626-1642. PubMed ID: 32981117
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Association between dd-cfDNA levels, de novo donor specific antibodies, and eGFR decline: An analysis of the DART cohort.
    Sawinski DL; Mehta S; Alhamad T; Bromberg JS; Fischbach B; Aeschbacher T; Ghosh S; Shekhtman G; Dholakia S; Brennan DC; Poggio E; Bloom RD; Jordan SC
    Clin Transplant; 2021 Sep; 35(9):e14402. PubMed ID: 34184326
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Randomized clinical trial of a novel donor-derived cfDNA test to detect rejection in CPV-simulated renal transplant patients.
    Peabody J; Billings P; Valdenor C; Demko Z; Moshkevich S; Tran M; Paculdo D
    Int Urol Nephrol; 2020 Aug; 52(8):1593-1601. PubMed ID: 32415610
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Initiation of noninvasive surveillance for allograft rejection in heart transplant patients > 1 year after transplant.
    Kewcharoen J; Kim J; Cummings MB; Leitner KB; Suzuki EMB; Banerjee D; Lum CJ
    Clin Transplant; 2022 Mar; 36(3):e14548. PubMed ID: 34843112
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Donor-Derived Cell-free DNA for Personalized Immunosuppression in Renal Transplantation.
    Oellerich M; Budde K; Osmanodja B; Bornemann-Kolatzki K; Beck J; Schütz E; Walson PD
    Ther Drug Monit; 2023 Feb; 45(1):20-25. PubMed ID: 36127770
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Graft-derived Cell-free DNA as a Noninvasive Biomarker of Cardiac Allograft Rejection: A Cohort Study on Clinical Validity and Confounding Factors.
    Knüttgen F; Beck J; Dittrich M; Oellerich M; Zittermann A; Schulz U; Fuchs U; Knabbe C; Schütz E; Gummert J; Birschmann I
    Transplantation; 2022 Mar; 106(3):615-622. PubMed ID: 33653997
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Donor-derived, cell-free DNA levels by next-generation targeted sequencing are elevated in allograft rejection after lung transplantation.
    Khush KK; De Vlaminck I; Luikart H; Ross DJ; Nicolls MR
    ERJ Open Res; 2021 Jan; 7(1):. PubMed ID: 33532456
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Organizing pneumonia is associated with molecular allograft injury and the development of antibody-mediated rejection.
    Keller MB; Tian X; Jang MK; Meda R; Charya A; Ozisik D; Berry GJ; Marboe CC; Kong H; Ponor IL; Aryal S; Orens JB; Shah PD; Nathan SD; Agbor-Enoh S
    J Heart Lung Transplant; 2024 Apr; 43(4):563-570. PubMed ID: 37972825
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Donor-derived Cell-free DNA in Solid-organ Transplant Diagnostics: Indications, Limitations, and Future Directions.
    Kataria A; Kumar D; Gupta G
    Transplantation; 2021 Jun; 105(6):1203-1211. PubMed ID: 33534526
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cell-free DNA in lung transplantation: research tool or clinical workhorse?
    Keller M; Agbor-Enoh S
    Curr Opin Organ Transplant; 2022 Jun; 27(3):177-183. PubMed ID: 35649108
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Preliminary clinical experience applying donor-derived cell-free DNA to discern rejection in pediatric liver transplant recipients.
    Zhao D; Zhou T; Luo Y; Wu C; Xu D; Zhong C; Cong W; Liu Q; Zhang J; Xia Q
    Sci Rep; 2021 Jan; 11(1):1138. PubMed ID: 33441886
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Early findings after integration of donor-derived cell-free DNA into clinical care following pediatric heart transplantation.
    Feingold B; Rose-Felker K; West SC; Zinn MD; Berman P; Moninger A; Huston A; Stinner B; Xu Q; Zeevi A; Miller SA
    Pediatr Transplant; 2022 Feb; 26(1):e14124. PubMed ID: 34420244
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Donor-derived cell-free DNA levels predict graft injury in liver transplant recipients.
    Levitsky J; Kandpal M; Guo K; Kleiboeker S; Sinha R; Abecassis M
    Am J Transplant; 2022 Feb; 22(2):532-540. PubMed ID: 34510731
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.